Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T)

Vaccine

Volumn 16, Issue 6, 1998, Pages 637-642

  Bell, Frank ^a   Heath, Paul ^b   Shackley, Fiona ^b   MacLennan, Jenny ^b   Shearstone, Nicola ^a   Diggle, Linda ^b   Griffiths, Helen ^c   Moxon, E Richard ^b   Finn, Adam ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Acellular pertussis vaccine; Combination vaccine; Hib vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; IMMUNOGLOBULIN G ANTIBODY; ORAL POLIOMYELITIS VACCINE; PERTUSSIS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MIXTURE; HUMAN; IMMUNIZATION; INFANT; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032054005     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)84511-2     Document Type: Article

References (45)

1. 1 Greco, D., Salmaso, S. and Mastrantonio, P. et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 1996, 334, 341-348.
2. 2 Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E. and Storsaeter, J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 1996, 334, 349-355.
3. 3 Brown, F., Greco, D., Mastrantonio, S., Salmaso, S. and Wassilak, S. Pertussis vaccine trials. Devel. Biol. Stand. 1997, 89, 1-403.
4. 4 Marwick, C. Acellular pertussis vaccine is licensed for infants. JAMA 1996, 276, 516-518.
5. 5 Department of Health. Combined Hib/DTP vaccines. CMO's Update 1996, 10, 1.
6. 6 U.K. Departments of Health. Immunisation against Infectious Disease (Eds Salisbury, D. and Begg, N.T.). HMSO, London, 1996, pp. 21, 80.
7. 7 Ferreccio, C., Clemens, J. and Avendano, A. et al. The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 1991, 10, 764-771.
8. 8 Avendano, A., Ferreccio, C. and Lagos, R. et al. Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four and six months of age. Pediatr. Infect. Dis. J. 1993, 12, 638-643.
9. 9 Gold, R., Scheifele, D. and Barreto, L. et al. Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four and six months of age. Pediatr. Infect. Dis. J. 1994, 13, 348-355.
10. 10 Miller, M.A., Meschievitz, C.K., Ballanco, G.A. and Daum, R.S. Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics 1995, 95, 522-527.
11. 11 Scheifele, D., Barreto, L., Meekison, W., Guasparini, R. and Friesen, B. Can Haemophilus influenzae type b-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? Can. Med. Assoc. J. 1995, 149, 1105-1112.
12. 12 Paradiso, P.R., Hogerman, D.A. and Madore, D.V. et al. Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993, 92, 827-832.
13. 13 Eskola, J., Olander, R., Hovi, T., Litmanen, L., Peltola, S. and Kayhty, H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 1996, 348, 1688-1692.
14. 14 Greenberg, D.P., Wong, V.K., Partridge, S., Chang, S.J., Howe, B.J. and Ward, J.I. Immunogenicity of a booster dose of Hib conjugate vaccine in children with impaired immune responses following primary vaccination with DTaP-Hep B-PRP-T vaccine. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996, p. 154 (Abstract)
15. 15 Zepp, F., Schmitt, H.J. and Kaufhold, A. et al. Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur. J. Pediatr. 1997, 156, 18-24.
16. 16 Booy, R., Taylor, S.A. and Dobson, S.R. et al. Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule. Arch. Dis. Child. 1992, 67, 475-478.
17. 17 Fritzell, B. and Plotkin, S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J. Pediatr. 1992, 121, 355-362.
18. 18 Booy, R., Hodgson, S. and Carpenter. L. et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994, 344, 362-366.
19. 19 Bell, F., Martin, A., Blondeau, C., Thornton, C., Chaplais, J. and Finn, A. Combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccines for primary immunisation. Arch. Dis. Child. 1996, 75, 298-303.
20. 20 Begg, N.T., Miller, E. and Fairley, C.K. et al. Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type b conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine 1995, 13, 1547-1550.
21. 21 Mallet, E., Hoffenbach, A., Salomon, H., Blondeau, C. and Fritzell, B. Primary immunization with combined, acellular DTaP-IPV-Act-HIB vaccine given at 2-3-4 or 2-4-6 months of age. 14th Meeting of the European Society for Paediatric Infectious Diseases 1996 (Abstract 19)
22. 22 Langue, J., David, T., Roussel, F., Pines, E. and Hoffenbach, A. Safety and immunogenicity of DTaP-IPV and Act-Hib vaccines administered either combined or separately to infants at 2, 3 and 4 months of age. 15th Meeting of the European Society for Paediatric Infectious Diseases 1997 (Abstract 79)
23. 23 Pichichero, M., Latiolais, T., Bernstein, D. et al. Immunogenicity and safety of a combination DTaP/PRP-T vaccine in 2, 4 and 6 months old infants. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996, p. 160 (Abstract)
24. 24 Liese, J.G., Harzer, E., Hosbach, P., Froeschle, J., Meschievitz, C.K. and Belohradsky, B.H. Hib antibody response of a combined DTaP-PRP-T conjugate vaccine compared to separate injections in infants. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy 1996, p. 162 (Abstract)
25. 25 Robbins, J.B., Parke, J.C., Schneerson, R. and Whisnant, J.K. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 1973, 7, 103-110.
26. 26 Santosham, M., Reid, R. and Ambrosino, D.M. et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N. Engl. J. Med. 1987, 317, 923-929.
27. 27 Peltola, H., Kayhty, H., Virtanen, M. and Makela. P.H. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N. Engl. J. Med. 1984, 310, 1561-1566.
28. 28 Kayhty, H., Peltola, K., Karanko, V. and Makela, P.H. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 1983, 147, 1110.
29. 29 Anderson, P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J. Infect. Dis. 1984, 149, 1034-1035.
30. 30 Granoff, D.M., Holmes, S.J. and Osterholm, M.T. et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 1993, 168, 663-671.
31. 31 Eskola, J., Kayhty, H. and Takala, A.K. et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N. Engl. J. Med. 1990, 323, 1381-1387.
32. 32 Barbour, M.L., Mayon-White, R.T., Coles, C., Crook, D.W. and Moxon, E.R. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J. Infect. Dis. 1995, 171, 93-98.
33. 33 Booy, R., Heath, P.T., Slack, M.P.E., Begg, N. and Moxon, E.R. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster. Lancet 1997, 349, 1197-1202.
34. 34 Parke, J.C., Schneerson, R. and Reimer, C. et al. Clinical and immunologic responses to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants injected at 3, 5, 7, and 18 months of age. J. Pediatr. 1991, 118, 184-190.
35. 35 Scheifele, D.W., Meekison, W., Guasparini, R., Roberts, A., Barreto, L.T.J. and Wiltsey, S. Evaluation of booster doses of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in 18-month-old children. Vaccine 1995, 13, 104-108.
36. 36 Decker, M.D., Edwards, K.M., Bradley, R. and Palmer, P. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. J. Pediatr. 1993, 122, 410-413.
37. 37 Kurikka, S., Kayhty, H., Saarinen, L., Ronnberg, P.R., Eskola, J. and Makela, P.H. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J. Infect. Dis. 1995, 172, 1268-1272.
38. 38 Barbour, M.L., Booy, R. and Crook, D.W. et al. Haemophilus influenzae type b carriage and immunity four years after receiving the Haemophilus influenzae oligosaccharide-CRM197 (HbOC) conjugate vaccine. Pediatr. Infect. Dis. J. 1993, 12, 478-484.
39. 39 Schneerson, R. and Robbins, J.B. Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5. N. Engl. J. Med. 1975, 292, 1093-1096.
40. 40 Siber, G.R., Anderson, R., Habafy, M. and Gupta, R.K. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines. Vaccine 1995, 13, 525-531.
41. 41 Gupta, R.K. and Siber, G.R. Guinea-pig model for assessing interference in the immunogenicity of different components of a combination vaccine comprising of diphtheria, tetanus, acellular pertussis (Dtap) vaccine and Haemophilus influenzae type b capsular polysaccharide conjugate vaccine. WHO/IABS/NIBSC meeting on the control and standardization of acellular pertussis vaccines 26-27th Sept. 1996. NIBSC, Potters Bar, Herts, U.K. (Abstract)
42. 42 Schutze, M., Leclerc, C., Jolivet, M., Audibert, F. and Chedid, L. Carrier induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 1985, 135, 2319-2322.
43. 43 Kaplan, S.L., Lauer, B.A. and Ward, M.A. et al. Immunogenicity and safety of Haemophilus influenzae type b-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J. Pediatr. 1994, 124, 323-327.
44. 44 Vogel, F.R., Leclerc, C. and Schutze, M.P. et al. Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide. Cell Immunol. 1987, 107, 40-51.
45. 45 American Academy of Pediatrics Committee on Infectious Diseases. Recommended childhood immunization schedule - United States, January-December 1997. Pediatrics 1997, 99, 136.